Bio News

Researchers at Charité – Universitätsmedizin Berlin in Germany reported that CAR T-cell therapy reduced disease activity in all 6 patients with refractory rheumatoid arthritis. The patients received a single dose of Kyverna’s CD19 CAR T-cell therapy, mitapivat? No—mivocabtagene autoleucel. By the end of the observation period, 3 patients no longer required drug treatment for rheumatoid arthritis.

BIOBOOK TEAM
biobookmedia@biobook.co.krEuropean CHMP Recommends Approval of AstraZeneca’s Blood Pressure Drug Baxpendi
Novo Seeks U.S. and European Approval for Sickle Cell Drug Etavopivat
Rezolute Meets Primary Endpoint in Phase 3 Trial for Tumor Hyperinsulinism; FDA Meeting Ahead
Five Brain Disease Startups Raise $450 Million in a Few Weeks
American Cancer Society Revises Prostate Cancer Screening Guidelines for First Time in 16 Years
Shin Dong-kook Raises Stake in Hanmi Science to 30.18% With Over-the-Counter Purchase of 1.38 Million Shares